Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the vaxneuvance market?

In the last few years, the vaxneuvance market has witnessed an XX (HCAGR). It is expected to expand from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. The growth observed in the historical phase can be traced to the surge in pneumococcal diseases, an increase in the elderly population, more supportive regulatory approvals, increased government funding for vaccines, and the surge in travel and globalization.

What will be the vaxneuvance market size in the future?

Expectations indicate that the vaxneuvance market is set to experience a compound annual growth rate (CAGR) of XX% in the upcoming years, projecting to reach a substantial value of $XX million in 2029. The projected expansion during the forecast period can be credited to several factors such as the growth of chronic diseases, the rise in antimicrobial resistance, and an increase in respiratory infections among children. Increasing cases amongst immunocompromised populations and enhancements in healthcare investments also play a major role. Future trends during the forecast period include the design of needle-free vaccine delivery systems, improvements in cold-chain technologies, the implementation of AI-enhanced supply chain optimization, digital health records integration for immunization tracking, and groundbreaking improvements in adjuvant systems to facilitate immune response.

Get your vaxneuvance market report here!

https://www.thebusinessresearchcompany.com/report/vaxneuvance-global-market-report

What main drivers are fueling expansion in the vaxneuvance market?

The rise in pneumonia cases is anticipated to fuel the expansion of the vaxneuvance market. Pneumonia, an infection that triggers inflammation in the lungs’ air sacs which often fill with fluid or pus, leads to symptoms such as coughing, high temperature, and difficulty breathing. Factors propelling the surge in pneumonia cases include bacterial and viral infections, compromised immunity, air pollution, and an increasing elderly population, which are more prone to respiratory infections. Vaxneuvance protects patients from pneumonia caused by 15 types of Streptococcus pneumoniae, thereby lowering the possibility of severe infections and related complications. As an illustration, in 2024, the Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) average score escalated to 56% across 15 nations, up 2% from 54% in 2023, as per the data from Johns Hopkins University, a research-based US institution. As a result, the vaxneuvance market is growing due to the increasing incidence of pneumonia.

What key areas define the segmentation of the global vaxneuvance market?

The vaxneuvance market covered in this report is segmented –

1) By Indication: Pneumonia; Meningitis; Sepsis; Bacteremia; Otitis Media

2) By Distribution Channel: Pharmacies; Hospitals

3) By End User: Adults; Children; Geriatric Population

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20428&type=smp

Who are the dominant players expanding their reach in the vaxneuvance market?

Major companies operating in the vaxneuvance market are Merck & Co. Inc.

How are evolving market trends shaping vaxneuvance Strategies?

A principal trend in the vaxneuvance market involves broadening its target demographic through expanded vaccine indications. These expanded indications cater to unmet medical requirements and augment the usefulness of the vaccine in thwarting pneumococcal diseases in various age brackets. For example, in June 2022, the pharmaceutical corporation based in the US, Merck & Co. Inc., proclaimed that the United States Food and Drug Administration (FDA) extended the approval of vaxneuvance to cover children from 6 weeks to 17 years of age for the prevention of invasive pneumococcal disease brought about by 15 serotypes. This authorization underlines its clinical importance but cautions against its use in individuals who possess severe allergies to its constituents.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20428

Which regions are emerging as leaders in the vaxneuvance market?

North America was the largest region in the vaxneuvance market in 2024. The regions covered in the vaxneuvance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Pediatric Vaccine Global Market Report 2025

https://thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report

Companion Animal Veterinary Vaccines Global Market Report 2025

https://thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

Cancer Vaccines Global Market Report 2025

https://thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: